BLACK DIAMOND THERAPEUTICS, INC. Reclassifications of Temporary to Permanent Equity
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Reclassifications of Temporary to Permanent Equity of $200.57 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-25.
Discontinued › Shareholders' Equity
us-gaap:ReclassificationsOfTemporaryToPermanentEquity · last filed 2021-03-25
- BLACK DIAMOND THERAPEUTICS, INC. reclassifications of temporary to permanent equity for the quarter ending 2020-03-31 was $200.57M.
- BLACK DIAMOND THERAPEUTICS, INC. reclassifications of temporary to permanent equity for fiscal 2020 was $200.57M.
| Period end | Reclassifications of Temporary to Permanent Equity 3 month | Reclassifications of Temporary to Permanent Equity 12 month |
|---|---|---|
| 2020-12-31 | $200.57M 10-K · filed 2021-03-25 | |
| 2020-03-31 | $200.57M 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |